CLL Microlearning Series – Video #7: Empowering Patients Through Choice and Communication
Empowering Patients Through Choice and Communication
Adherence is essential for the long-term effectiveness of zanubrutinib, an oral BTK inhibitor taken indefinitely until progression or intolerance.
In this video, an APP specializing in CLL discusses how proactive communication, side-effect counseling, and strong clinician–patient rapport can help identify and address barriers to adherence early.
You’ll Learn:
- Why adherence is critical for the sustained effectiveness of long-term zanubrutinib therapy
- How untreated or bothersome side effects can lead to missed doses
- Ways clinicians can support adherence through ongoing counseling and expectation-setting
- The importance of open communication to uncover intentional or unintentional missed doses
- Practical strategies to improve adherence, such as reminders, support-person involvement, and early identification of financial or tolerability issues
- How multidisciplinary teamwork (APPs, pharmacists, nurses, and physicians) helps resolve adherence barriers quickly